Low-Dose Radioimmunotherapy (90Y-PAM4) Combined with Gemcitabine for the Treatment of Experimental Pancreatic Cancer

• Published in: Clinical cancer research 2003-09, Vol.9 (10), p.3929s
• Main Authors: David V. Gold, Keith Schutsky, David Modrak, Thomas M. Cardillo
• Format: Article
• Language: English
• ISSN: 1078-0432; 1557-3265

Purpose: Monoclonal antibody PAM4 is reactive with the MUC1 mucin as expressed by >85% of human pancreatic cancers. Significant antitumor effects have been demonstrated using radiolabeled PAM4 for radioimmunotherapy (RAIT) of experimental pancreatic cancer. The goal of the present study was to determine whether the addition of low-dose 90 Y-PAM4 RAIT to a clinically relevant regimen of gemcitabine chemotherapy would provide enhanced antitumor efficacy over that observed by chemotherapy alone without the addition of significant toxicity to normal tissues. Experimental Design: Mice bearing human pancreatic tumor xenografts (CaPan1) were administered three cycles of gemcitabine chemotherapy (1000 mg/m 2 /week for 3 weeks with 1 week off) concomitant with 90 Y-labeled PAM4 RAIT (25 μCi; 10% of the single agent MTD) given at weeks 0, 4, and 7. Control groups of mice received chemotherapy alone, 90 Y-PAM4 RAIT alone, or an equidose of 90 Y-labeled nontargeting control antibody with and without gemcitabine. Results: Mice that received 90 Y-PAM4 RAIT with gemcitabine had tumors that were significantly smaller in size than all of the other treatment groups ( P < 0.005). A median survival of 24 weeks was achieved in mice that received the combined treatment versus 10 weeks for mice that received only gemcitabine ( P < 0.001) and 16 weeks for mice that received only 90 Y-PAM4 RAIT ( P < 0.040). The combined treatment regimen was well tolerated. Conclusions: A combined chemoimmunotherapy and RAIT approach using gemcitabine and low-dose 90 Y-PAM4 provided significantly increased antitumor efficacy than was observed for each treatment arm given alone. Importantly, the enhanced antitumor efficacy was achieved with minimal toxicity to normal tissues. These studies provide justification for clinical trials using the combined modality treatment for patients with pancreatic cancer.